Loading...
•
Mar 31, 2021
Sangamo Q1 2021 Earnings Report
Reported recent business highlights and first quarter 2021 financial results.
Key Takeaways
Sangamo Therapeutics reported a consolidated net loss of $45.9 million, or $0.32 per share, for the first quarter ended March 31, 2021. Revenues for the quarter were $26.3 million, primarily due to recognition of upfront license fees and research reimbursements from Biogen and Novartis collaborations.
Completed enrollment of patients in Pfizer’s lead-in study to the registrational Phase 3 AFFINE clinical trial of giroctocogene fitelparvovec for hemophilia A.
Received Fast Track Designation from the FDA and Orphan Designation from the EMA for SAR445136, a cell therapy product candidate for sickle cell disease, developed in collaboration with Sanofi.
Initiated the Phase 1/2 STEADFAST clinical study evaluating TX200, a wholly-owned autologous HLA-A2 CAR-Treg cell therapy product candidate treating patients receiving a HLA-A2 mismatched kidney from a living donor.
Published preclinical data on tau- and alpha-synuclein-targeted zinc finger transcriptional repressors in Science Advances and at the 15th International Conference on Alzheimer’s & Parkinson’s Diseases (ADPD), respectively.
Forward Guidance
Sangamo expects total operating expenses on a GAAP basis to be in the range of approximately $285 million to $305 million. On a non-GAAP basis, total operating expenses, excluding estimated non-cash stock-based compensation expense of approximately $30 million, are expected to be in the range of approximately $255 million to $275 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...